Exhibit 99.1

ASX ANNOUNCEMENT 31 January 2018 Results from 31 January 2018 General Meeting Melbourne, Australia; 31 January 2018: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”) advises that a General Meeting of shareholders that had been requisitioned pursuant to section 249D of the Corporations Act was held at 10.00 am today (Melbourne time). At the commencement of the meeting, the appointed Chairman of the meeting, advised that resolution 1, removal of Dr Malcolm R. Brandon as a Director and resolution 2, removal of Mr Grahame Leonard, AM, as a Director had been withdrawn as a result of the resignations of these Directors. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001(Cth), details of the proxies received in respect of each resolution put to shareholders are set out in Table 1 to this announcement. The four (4) resolutions that were put before the shareholders were passed on a show of hands. FOR FURTHER INFORMATION PLEASE CONTACT Dr Paul Kasian Director Genetic Technologies Limited + 61 3 8412 7000 Jason Wong (USA)) Blueprint Life Science Group +1 (415) 375 3340, Ext. 4 About Genetic Technologies Limited Genetic Technologies is a molecular diagnostics company that offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGenplus is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer. The Company markets BREVAGenplus, through its U.S. subsidiary Phenogen Sciences Inc., to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons). For more information, please visit www.brevagenplus.com and www.phenogensciences.com. Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com Genetic Technologies Limited • Website: www.gtglabs.com • Email: info@gtglabs.comABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040

Safe Harbor Statement Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC. Genetic Technologies Limited • Website: www.gtglabs.com • Email: info@gtglabs.comABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040

Table 1 - Proxy results for 31 January 2018 General Meeting *Discretionary votes in favour of the Chair of the meeting – voted against the resolution Note: The Company currently has a total of 2,435,282,724 ordinary shares on issue and 3,596 registered shareholders. Genetic Technologies Limited • Website: www.gtglabs.com • Email: info@gtglabs.comABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040 Manner in which the securityholder directed the proxy vote Description of Resolution For Against Discretionary Chairman * Discretionary Other Abstain 1. Removal of Dr M Brandon as a Director Numbers of votes received Resolution withdrawn at commencement of the meeting 2. Removal of Mr G Leonard as a Director Numbers of votes received Resolution withdrawn at commencement of the meeting 3. Removal of Mr E Buccilli as a Director Numbers of votes received Percentage of votes cast 344,848,740 56.9% 260,318,699 43.0% 334,728 0.1% 21,560 0.0% 2,455,200 4. Appointment of Mr S Lee as a Director Numbers of votes received Percentage of votes cast 345,391,965 57.0% 259,553,860 42.9% 553,914 0.1% 21,560 0.0% 2,457,628 5 Appointment of Mr P Rubenstein as a Director Numbers of votes received Percentage of votes cast 345,523,080 57.1% 259,441,345 42.8% 553,914 0.1% 21,560 0.0% 2,439,028 6 Appointment of Mr J Muchnicki as a Director Numbers of votes received Percentage of votes cast 344,037,980 56.8% 260,840,495 43.1% 553,914 0.1% 21,560 0.0% 2,524,978